ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report
BackgroundEntrectinib, a recently approved multikinase inhibitor indicated for advanced ROS1-positive non-small cell lung cancer (NSCLC), has demonstrated significant survival benefits in metastatic disease. However, it carries risks of severe cardiotoxicity. We report the successful management of e...
Saved in:
| Main Authors: | Qi Yujuan, Ma Xiaozhong, Wu Zhenhua, Bai Yunpeng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1626318/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term left ventricular ejection function in fulminant and non-fulminant myocarditis: A multicenter study in China
by: Guangling Li, et al.
Published: (2025-08-01) -
Analysis of risk factors affecting prognosis of fulminant myocarditis in children: a ten-year single-center study
by: Jia Yuan, et al.
Published: (2025-03-01) -
Acute myocarditis during adjuvant therapies for breast cancer: a case report
by: Yumiko Ushiyama, et al.
Published: (2023-03-01) -
cfDNA methylation detection as potential liquid biopsy of multiple organ injury in myocarditis patients
by: Yangchao Zhao, et al.
Published: (2025-06-01) -
Development and internal validation of the PROFIT and POSITIVE prognostic nomograms for patients undergoing VA-ECMO therapy
by: Shirui Qian, et al.
Published: (2025-07-01)